SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 21.5% in March

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 48,500 shares, a drop of 21.5% from the February 28th total of 61,800 shares. Based on an average daily volume of 75,800 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after buying an additional 86,764 shares in the last quarter. Green Alpha Advisors LLC grew its stake in shares of SOPHiA GENETICS by 119.3% in the 4th quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock worth $145,000 after purchasing an additional 25,686 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $70,000. Millennium Management LLC raised its holdings in shares of SOPHiA GENETICS by 6.5% in the 4th quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock worth $2,180,000 after purchasing an additional 42,689 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in SOPHiA GENETICS by 23.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock valued at $68,000 after purchasing an additional 4,115 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SOPH shares. Craig Hallum began coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 target price on the stock. BTIG Research set a $5.00 price target on shares of SOPHiA GENETICS in a report on Thursday, March 6th.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock traded up $0.06 during trading on Tuesday, hitting $3.38. 525 shares of the stock were exchanged, compared to its average volume of 68,238. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. SOPHiA GENETICS has a 12 month low of $2.70 and a 12 month high of $6.28. The stock’s fifty day moving average is $3.61 and its 200 day moving average is $3.49. The stock has a market cap of $225.40 million, a PE ratio of -3.10 and a beta of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, March 4th. The company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The firm had revenue of $17.73 million for the quarter, compared to analysts’ expectations of $17.71 million. As a group, sell-side analysts anticipate that SOPHiA GENETICS will post -0.96 EPS for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.